Fangzhou Inc. featured in Fortune China’s Best Designs 2026 list for AI-driven chronic care platform

SHANGHAI, Sept. 03, 2026 /CourierPR/ -- Fangzhou Inc., a leading provider of AI-driven Internet healthcare solutions, has been recognized for its innovative "AI + Chronic Care" platform, which has been included in Fortune China’s Best Designs 2026 list. This accolade highlights Fangzhou’s commitment to leveraging artificial intelligence to enhance chronic disease management.

Now in its fifth year, the Fortune China Best Designs list evaluates projects based on innovation, real-world implementation, industry value, and broader social impact. This year, the list particularly focuses on artificial intelligence, recognizing projects that address industry challenges and demonstrate commercial potential and social value. Fangzhou’s inclusion in the list underscores the practicality, scalability, and commercial viability of its AI-powered chronic care model.

Chronic disease management remains a critical component of China’s public healthcare system, but traditional models face significant challenges, including fragmented services, high labor costs, inconsistent patient follow-ups, and limited personalization. To address these issues, Fangzhou began exploring AI applications in healthcare as early as 2022.

In 2025, Fangzhou launched its "AI + Chronic Care" service model, powered by its proprietary “XingShi” Large Language Model (XS LLM). This platform integrates AI functionality throughout the patient journey, from health monitoring and medication guidance to follow-up management and health education. By connecting fragmented services, the platform provides a more seamless and personalized care experience.

In 2026, as Fangzhou scaled the deployment of XS LLM, the model delivered significant benefits across both patient and physician workflows: - Workflow Optimization: Streamlined service delivery by automating routine tasks and processes, enhancing operational efficiency. - Enhanced Care Quality & Patient Adherence: Integrated professional clinical guidance into daily health management, empowering individuals to build healthier routines and manage chronic conditions more effectively.

Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 59.8 million registered users and 262,000 physicians as of June 30, 2026. The company specializes in delivering tailored medical care and AI-enabled precision medicine solutions. This recognition marks another milestone in Fangzhou’s strategic evolution into a comprehensive personal health service partner.

Looking ahead, the company plans to integrate AI technology across broader healthcare scenarios, driving industry-wide efficiency and supporting the long-term development of digital healthcare.